Evaluation of XYA02 in Patients With Advanced Solid Tumors

Sponsor
XYone Therapeutics, Inc
Study ID
NCT07670312
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • XYA02 — BIOLOGICAL
    IV infusion

Study Details

This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.

Key Dates

First listed
Jun 26, 2026
Start date
Jul 15, 2026
Status verified
Jul 2026
Primary completion
Jul 15, 2029
Completion
Jul 15, 2030

Study Design

Enrollment
190 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation
    Participants with locally advanced, relapsed, or refractory tumors who will receive an intravenous (IV) infusion of XYA02.
  • Experimental: Dose Expansion
    Multiple expansion cohorts targeting various advanced solid tumors who will receive an intravenous (IV) infusion of XYA02.

Primary Outcome Measure

Frequency of Treatment Emergent Adverse Events of XYA02 [ Time Frame: From enrollment for a minimum of 16 weeks ]

Central Contacts

Find similar trials

Nationwide
Colorectal cancer trialsLung cancer trialsOvarian cancer trialsPancreatic cancer trialsOncology trialsGI oncology trialsLung oncology trialsLung disease trialsGynecologic oncology trialsWomen's health trials

Related Studies